SLU-PP-915: the orally active exercise-mimetic ERR agonist
A next-generation, orally bioavailable pan-ERR agonist from the same lab as SLU-PP-332 — what the preclinical science shows, how it differs from 332, and the honest gaps. Animal data only; no human studies exist.
Animal data only as of 2026
📋 On this page
How It Works
Activates all three estrogen-related receptors (ERRα, β, γ) — orphan nuclear receptors that drive mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation and the Krebs cycle, and are essential for skeletal-muscle adaptation to aerobic exercise. SLU-PP-915 was identified through the pharmacological evaluation of a new, potent pan-ERR chemical series. [PMID 37421886, 41421047]
Built from a chemically distinct scaffold that gives 915 the oral activity SLU-PP-332 lacks. In mice, an orally active ERR agonist enhanced aerobic exercise capacity — comparable to injected 332 in these mouse studies. Oral bioavailability is 915's single headline advantage over 332. [PMID 41421047, 37421886]
In mice, 915 induces DDIT4 (an acute-aerobic-exercise gene) and mitochondrial genes to levels matching or exceeding treadmill running, and synergizes with exercise training to push aerobic exercise capacity higher still. [PMID 41421047]
Across the SLU-PP series, pan-ERR agonism raises energy expenditure and fatty-acid oxidation and improves insulin sensitivity in metabolic-syndrome models (SLU-PP-332), and novel pan-ERR agonists ameliorate heart failure by enhancing cardiac fatty-acid metabolism and mitochondrial function. All animal data. [PMID 37739806, 37961903]
What the Data Shows
SLU-PP-915 vs SLU-PP-332: What Actually Differs
Both are pan-ERR agonist "exercise mimetics" from the same Saint Louis University lab (Burris). The meaningful difference is the route of activity, not the target. Everything below is animal / in-vitro data — neither compound has any human data.
| SLU-PP-915 | SLU-PP-332 | |
|---|---|---|
| Target | Pan-ERR agonist (ERRα/β/γ) | ERR agonist (ERRα/γ emphasis) |
| Oral bioavailability | Yes — orally active in mice | No — not orally active |
| Aerobic exercise capacity (mice) | Increased; comparable to injected 332 in mice | Increased (injected) |
| Exercise-gene induction | DDIT4 + mitochondrial genes to running levels; synergizes with training | Upregulates exercise-responsive genes |
| Human data | None | None |
| Regulatory status | Research chemical, not approved | Research chemical, not approved |
Key Takeaways
- SLU-PP-915 is a pan-ERR agonist (activates ERRα, β and γ) — same target family and lab (Saint Louis University / Burris) as SLU-PP-332.
- Its one headline advantage over SLU-PP-332 is oral bioavailability; 332 is not orally active.
- In mice, oral 915 enhances aerobic exercise capacity (running distance and duration) comparably to injected 332.
- It induces the acute-exercise gene DDIT4 and mitochondrial genes to levels matching or exceeding treadmill running, and synergizes with training.
- Across the SLU-PP series, pan-ERR agonism improves metabolic-syndrome markers and ameliorates heart failure in animal models.
- Anti-doping labs have already characterized 915's metabolites — it is on the radar as a potential exercise-mimetic doping agent.
- ZERO human data of any kind — every published result is mouse or in-vitro. Safety, dosing and efficacy in people are entirely unknown.
- No human dose exists. There is no established protocol, and nothing here is a dosing recommendation.
- No long-term safety profile; the effects of chronic ERR activation in humans are uncharacterized.
- Not approved and not a supplement — it is an early-stage research chemical sold "for research use only".
- Whether the mouse exercise-mimetic effect translates to human fitness, fat loss or disease outcomes is entirely unproven.
Frequently Asked Questions
What is SLU-PP-915?
SLU-PP-915 is a synthetic pan-ERR agonist ("exercise mimetic") developed at Saint Louis University — a chemically distinct, orally bioavailable analog of SLU-PP-332 that activates the ERRα/β/γ nuclear receptors regulating mitochondrial and fatty-acid-oxidation genes. All published data is from animal and in-vitro studies.
How is SLU-PP-915 different from SLU-PP-332?
Same pan-ERR mechanism, but 915 is orally bioavailable whereas 332 is not. In mice, oral 915 enhanced aerobic exercise capacity, comparable to injected 332 in these preclinical studies.
Is SLU-PP-915 an exercise mimetic?
In animals it reproduces key aerobic-exercise signals (DDIT4 and mitochondrial gene induction) without exercise, and synergizes with training — but there is no human evidence it can replace exercise.
Is there any human data on SLU-PP-915?
No. There are zero human studies. All published work is preclinical (mouse and in-vitro). Human safety, dosing and efficacy are unknown, and there is no recommended dose.
Is SLU-PP-915 detectable in drug testing?
Anti-doping researchers have already mapped its in-vitro metabolites for sports drug-testing programs, so detection methods are actively being developed.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
SLU-PP-915 is an early-stage research chemical with no human clinical data. It has not been tested in humans; there is no established dose, no safety profile, and no efficacy claim can be made for human use. Nothing here is a recommendation to obtain or use it. Do not self-administer this compound.